AliveCor's Next App Could Save You From a Heart Attack
Posted on November 14, 2018 by Medtech[y] Staff
AliveCor, maker of ECG software and hardware for the iPhone and other mobile devices, received another impressive victory this week as an international study found that their smartphone app was nearly as accurate as a 12-lead ECG in determining if a patient is having an ST-segment elevation myocardial infarction (STEMI).
Researchers from Intermountain Medical Center Heart Institute in Salt Lake City led the study and followed 204 patients with chest pain. Patients received both a standard 12-lead ECG and an ECG through the AliveCor app, which is administered through a smartphone such as an iPhone.
Full house on hand for Dr. Brent Muhlestein’s #AHA18 study presentation on @AliveCor ECG mobile smartphone app that was found to be nearly as accurate as standard hospital 12-lead ECGs in diagnosing #STEMI heart attacks. @Intermountain #HeartInstitute @AHAMeetings pic.twitter.com/gtqWcQTlxG— Jess Gomez (@Jess_Intermtn) November 11, 2018
AliveCor was the first to receive FDA-clearance for a medical-device accessory to the Apple Watch.
Aside from nearly being on par with the gold standard of a 12-lead ECG, this data could open the door to many possibilities for patients as access and cost are no longer a barrier in getting a potentially life-saving ECG. Patients currently presenting with STEMI like symptoms have to go to an emergency room or their physicians office which is expensive and inconvenient, especially if the symptoms are nothing more than indigestion or gas.
The ability to have a device that is currently less than $100 (Not the same device used in the study) and has similar accuracy of the gold-standard, could change the way patients are monitored throughout the world. While the AliveCor KardiaMobile ECG Monitor and the KardiaBand for Apple Watch are currently used to detect Afib, studies like this give a glimpse of what the future may hold for devices from AliveCor.
The app used in the study requires patients to purchase a device with two electrical leads that will connect wirelessly with their smartphones, which would then connect to a free app. There is currently not a name for the device or a price but the cost will likely be much less than what it currently costs a general consumer to purchase a 12-lead ECG.
You can review the abstract here.